B7-H3 SADA

**B7-H3 SADA** is an investigational **pretargeted radioimmunotherapy** construct from **Y-mAbs Therapeutics** based on the company's **Self-Assembly DisAssembly** platform. It is an anti-B7-H3 antibody-derived construct designed to self-assemble for high-avidity tumor binding and then disassemble into smaller units to improve systemic clearance before administration of a radiolabeled hapten payload, with the goal of delivering tumor-targeted radiation while reducing off-target exposure. B7-H3 SADA has been described by Y-mAbs as a **preclinical** SADA program intended for **prostate cancer**, and broader company disclosures indicate the SADA platform is being developed for oncology and radiopharmaceutical applications. The molecular target is **B7-H3**, also known as **CD276**, a tumor-associated immune checkpoint protein broadly overexpressed across many solid tumors.

Other names

B7-H3-SADAB-7-H3-SADAB 7-H3-SADA